NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Can you please explain to me why it would be so out of grasp for NWBO to have come to the conclusion that pulling data from external trials ex IDH mutant was not feasible? And then to have concluded ok to be able to compare oranges with oranges for efficiency sake let's have our data include IDH mutant? For if you say this

Your other premise that maybe we could treat idh1 mutant is far fetched, as it is no longer GBM, and the sampling wouldn’t be big enough.

then that also would mean that all the trial data of the past including sock are invalid and NWBO would ex IDH mutant now have nothing to compare with which also mean that DCVAX L is now SOC and orphan by definition for the disease prior to May 2021 did not exist?

Also again what makes you think that the DCVAX L data would not be showcased ex idh-mutant just for trial efficiency sake not compared to external trial data?